Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.
Sarah E. S. Leary, MD, MS
Advertisement
Articles by Sarah E. S. Leary, MD, MS
Sarah E. S. Leary, MD, MS, discusses findings from the phase 2 FIREFLY-1 trial in pediatric patients with low-grade glioma.
Advertisement
Latest Updated Articles
Dr Leary on Tovorafenib in Pediatric Low-Grade GliomaJuly 26th 2023
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5